Clinical Significance of Preoperative CT and MR Imaging Findings in the Prediction of Postoperative Recurrence of Spinal Giant Cell Tumor of Bone.

OBJECTIVES To explore the predictive value of preoperative imaging in patients with spinal giant cell tumor of bone (GCTB) for postoperative recurrence and risk stratification. METHODS Clinical data for 62 cases of spinal GCTB diagnosed and treated at our hospital from 2008 to 2018 were identified. All patients were followed up for more than 2 years according to the clinical guidelines after surgery. Medical history data including baseline demographic and clinical characteristics, computed tomography (CT) and magnetic resonance imaging (MRI) findings of recurrent and non-recurrent patients were compared. Two musculoskeletal radiologists read the images and were blinded to the clinical data. The imaging features associated with postoperative recurrence were analyzed by multivariate logistic regression, and receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cutoff value of the largest lesion diameter predicting recurrence after surgery. RESULTS According to whether the disease recurred within the follow-up period, patients were divided into the recurrence group and the non-recurrence group. Of 62 patients (29 males and 33 females), 17 had recurrence and 45 did not. The recurrence rate was 27.4%. The mean follow-up time was 73.66 (± 32.92) months. The three major treatments were total en bloc spondylectomy (n = 26), intralesional spondylectomy (n = 20), and curettage(n = 16). A total of 16 CT and MRI features were analyzed. A univariate analysis showed no significant difference in age, sex, treatment, multi-vertebral body involvement, location, boundary, expansile mass, residual bone crest, paravertebral soft tissue mass, CT value, and MRI signal on T1-weighted imaging (WI), T2-WI, and T2-WI fat suppression (FS) sequences (P > 0.05). The largest lesion diameter [(4.68 ± 1.79) vs (5.92 ± 2.17) cm, t = 2.287, P = 0.026] and the vertebral compression fracture (51% vs 82%, χ2  = 5.005, P = 0.025) were significantly different between the non-recurrence and recurrence groups. Logistic regression analysis showed that both largest lesion diameter (odds ratio [OR], 1.584; 95% confidence interval [CI], 1.108-2.264; P = 0.012) and compression fracture (OR, 8.073; 95%CI, 1.481-11.003; P = 0.016) were independent predictors of postoperative recurrence. When we set the cutoff value for the largest lesion diameter at 4.2 cm, the sensitivity and specificity for distinguishing the recurrence and non-recurrence of GCTB were 94.1% and 42.2%, respectively, and the area under the curve (AUC) was 0.671. The combined model achieved a sensitivity, specificity and accuracy of 47.1%, 97.8% and 83.9%, respectively. CONCLUSIONS In spinal GCTB, maximum lesion diameter and the vertebral compression fracture are associated with tumor recurrence after surgery, which may provide helpful information for planning personalized treatment.

[1]  Jing Pang,et al.  Giant cell tumors of the mobile spine with invasion of adjacent vertebrae: an unusual imaging finding , 2021, BMC Musculoskeletal Disorders.

[2]  Zhongjun Liu,et al.  Imaging Features of Aggressive Giant Cell Tumors of the Mobile Spine: Retrospective Analysis of 101 Patients From Single Center , 2021, Global spine journal.

[3]  W. Guo,et al.  Analysis of clinical outcome for adolescent patients undergoing conservative nerve-sparing surgery based on the proposed resection classification for sacral giant cell tumor , 2020, Journal of Clinical Neuroscience.

[4]  M. Behbahani,et al.  Incidence, Management, and Outcomes of Spinal Giant Cell Tumor of Bone in Adult Patients: A National Cancer Database Analysis. , 2020, World neurosurgery.

[5]  Xiangyang Wang,et al.  Survival and prognosis in malignant giant cell tumor of bone: A population-based analysis from 1984 to 2013 , 2019, Journal of bone oncology.

[6]  Zhenhua Zhou,et al.  Clinical features and prognostic factors of pediatric spine giant cell tumors: report of 31 clinical cases in a single center. , 2019, The spine journal : official journal of the North American Spine Society.

[7]  Yu Zhou,et al.  Tumor immunohistochemistry and preoperative magnetic resonance imaging features predict local recurrence of giant cell tumor of bone following intralesional curettage , 2018, Oncology letters.

[8]  C. Montgomery,et al.  Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options , 2018, The Journal of Knee Surgery.

[9]  H. Tsuchiya,et al.  Total spondylectomy for Enneking stage III giant cell tumor of the mobile spine , 2018, European Spine Journal.

[10]  G. Quan,et al.  Risk Factors for Pathological Fracture and Metastatic Epidural Spinal Cord Compression in Patients With Spinal Metastases. , 2017, Orthopedics.

[11]  M. Bilsky,et al.  En Bloc Resection Versus Intralesional Surgery in the Treatment of Giant Cell Tumor of the Spine , 2017, Spine.

[12]  Zhongjun Liu,et al.  Recurrence Factors in Giant Cell Tumors of the Spine , 2017, Chinese medical journal.

[13]  Yifeng He,et al.  A prospective study on predicting local recurrence of giant cell tumour of bone by evaluating preoperative imaging features of the tumour around the knee joint , 2017, La radiologia medica.

[14]  Dongqi Li,et al.  Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone , 2016, World Journal of Surgical Oncology.

[15]  M. Bilgen,et al.  Prognostic value of p53 protein expression in giant cell tumor of bone. , 2015, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[16]  E. Pignotti,et al.  Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study , 2015, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[17]  F. Gao,et al.  Imaging appearance of giant cell tumour of the spine above the sacrum. , 2015, The British journal of radiology.

[18]  W. Xu,et al.  Treatment and outcome of primary aggressive giant cell tumor in the spine , 2015, European Spine Journal.

[19]  K. Veselý,et al.  [WHO classification of tumours of soft tissue and bone 2013: the main changes compared to the 3rd edition]. , 2014, Ceskoslovenska patologie.

[20]  M. A. Siddiqui,et al.  Risk Factors for Recurrence of Giant Cell Tumours of Bone , 2014, Journal of orthopaedic surgery.

[21]  M. Isobe,et al.  Tumor associated osteoclast-like giant cells promote tumor growth and lymphangiogenesis by secreting vascular endothelial growth factor-C. , 2014, Biochemical and biophysical research communications.

[22]  Cheng-Sheng Wang,et al.  Giant cell tumours of the mobile spine: characteristic imaging features and differential diagnosis , 2014, La radiologia medica.

[23]  Tsuyoshi Saito,et al.  p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1 , 2013, Virchows Archiv.

[24]  Han Wang,et al.  Giant cell tumour of bone: a new evaluating system is necessary , 2012, International Orthopaedics.

[25]  J. Eckardt,et al.  Giant Cell Tumor of Bone: Are We Stratifying Results Appropriately? , 2012, Clinical orthopaedics and related research.

[26]  F. Sim,et al.  Giant Cell Tumor of Bone: Risk Factors for Recurrence , 2011, Clinical orthopaedics and related research.

[27]  E. McCarthy,et al.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. , 2010, The Iowa orthopaedic journal.

[28]  R. Tillman,et al.  Impending fractures in giant cell tumours of the distal femur: incidence and outcome , 2006, International Orthopaedics.

[29]  R. Grimer,et al.  Does Curettage without Adjuvant Therapy Provide Low Recurrence Rates in Giant-Cell Tumors of Bone? , 2005, Clinical orthopaedics and related research.

[30]  M. Wuelling,et al.  Differential gene expression in stromal cells of human giant cell tumor of bone , 2004, Virchows Archiv.

[31]  M. Wülling,et al.  The origin of the neoplastic stromal cell in giant cell tumor of bone. , 2003, Human pathology.

[32]  S. Kumta,et al.  Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. , 2003, Life sciences.

[33]  K. Siebenrock,et al.  Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. , 1998, The Journal of bone and joint surgery. British volume.

[34]  C. J. Campbell,et al.  Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. , 1970, The Journal of bone and joint surgery. American volume.